AmunBio Analysis
What is AmunBio?
Next-gen oncolytic virus therapy for cancer
Location
Seattle, United States
Employees
1-10
Founded
2020
Product Features & Capabilities
- Engineered immunotherapeutic oncolytic viruses for cancer and hematological malignancies
Use Cases
Treat patients with solid tumors; Target hematological malignancies such as leukemia and lymphoma; Activate immune response against cancer cells; Destroy cancer cells directly; Develop therapies for rare cancers
Other Considerations
Early stage biotechnology company; Founded in 2020; HQ in Seattle, WA; Focus on engineered oncolytic virus platform
See something that needs updating? Suggest edits to this profile.